AIM4:Next StepNCT06572228
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
StatusActive, Not Recruiting
PhasePhase 4
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 24 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment reduced: 250 → 120 participants
- Trial status changed: Recruiting → Active, Not Recruiting
- Primary and study completion pushed from Dec 31, 2026 to Apr 24, 2027
- Trial sites reduced: 84 → 77 locations
- Minor Study sites revised (84)v23
- Minor Site details revised at 68 of 84 sitesv22
- Minor Site details revised at 1 of 84 sitesv21
- Minor Study sites: 82 to 84v20
Show 18 earlier versionsHide 18 earlier versions
- Minor Study sites revised (82)v19
- Minor Study sites revised (82)v18
- Minor Study sites: 81 to 82v17
- Minor Study sites: 80 to 81v16
- Minor Study sites: 79 to 80v15
- Minor Study sites: 78 to 79v14
- Minor Study sites: 77 to 78v13
- Minor Study sites: 75 to 77v12
- Minor Study sites: 66 to 75v11
- Minor Study sites: 50 to 66v10
- Minor Study sites: 48 to 50v9
- Minor Study sites: 46 to 48v8
- Minor Study sites: 33 to 46v7
- Minor Study sites: 29 to 33v6
- Minor Study sites: 24 to 29v5
- Minor Study sites: 20 to 24v4
- Minor Study sites: 16 to 20v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 16
- Start date changed from estimate of Sep 17, 2024 to Aug 26, 2024
- Study description expanded, about 7 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Annualized severe asthma exacerbation rate
Timeframe: Baseline through Week 52
Secondary (14)
Change in pre-bronchodilator Forced expiratory volume in the first second (FEV1)
Annualized cumulative dose of systemic corticosteroid exposure to treat severe asthma exacerbations
Change in Asthma Control Questionnaire (ACQ-5)
Proportion of participants achieving ACQ-5 <1.5
Change in pre-bronchodilator FEV1
Show 9 moreShow less
Change in percent predicted FEV1
Change in peak expiratory flow (PEF)
Change in forced vital capacity (FVC)
Change in forced expiratory flow (FEF) 25-75%
Change in FEV1: FVC ratio
Change in post-bronchodilator FEV1
Time to first severe exacerbation event
Proportion of participants achieving a 0.5-point improvement minimal clinically important difference (MCID) in ACQ-5
Incidence of Treatment-emergent adverse event (TEAEs)
Arms and interventions
Dupilumab + ICS/LABAExperimental
Randomized 1:1
Placebo + ICS/LABAPlacebo comparator
Randomized 1:1
Drugs: dupilumab, Matching Placebo, ICS/LABA
Sites
77 sites in 6 countries
United States 51, Poland 9, Germany 8, Canada 7, Denmark 1, Puerto Rico 1